Astrocyte Pharma Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
2ndary - Private
- Investors
-
27
Astrocyte Pharma General Information
Description
Developer of neuroprotective therapies designed to advance treatment for brain injuries and neurodegenerative disorders. The company's technology targets astrocyte activation and utilizes adenosine receptor agonism to enhance brain resilience, enabling the healthcare sector to improve recovery outcomes for patients with stroke and traumatic brain injury.
Contact Information
Website
www.astrocytepharma.comCorporate Office
- 93 Shennecossett Road
- Groton, CT 06340
- United States
Corporate Office
- 93 Shennecossett Road
- Groton, CT 06340
- United States
Astrocyte Pharma Timeline
Astrocyte Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Secondary Transaction - Private | 01-Aug-2026 | Completed | Clinical Trials - Phase 2 | |||
| 11. Later Stage VC (Series B2) | 15-May-2026 | Completed | Clinical Trials - Phase 2 | |||
| 10. Grant | 17-Jun-2025 | Completed | Clinical Trials - Phase 2 | |||
| 9. Debt - General | 16-Dec-2024 | Completed | Clinical Trials - Phase 1 | |||
| 8. Later Stage VC | 18-Aug-2023 | Completed | Clinical Trials - Phase 1 | |||
| 7. Grant | 01-Jan-2023 | Completed | Clinical Trials - Phase 1 | |||
| 6. Grant | 08-Sep-2021 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series A) | 30-Apr-2021 | Completed | Clinical Trials - Phase 1 | |||
| 4. Grant | 19-Sep-2018 | $3.29M | $2.42M | Completed | Pre-Clinical Trials | |
| 3. Early Stage VC (Series A) | 01-May-2018 | $2.42M | Completed | Startup |
Astrocyte Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A | 24,324,450 | $0.000100 | 8% | $0.38 | $0.38 | 1x | $0.38 | 21.32% |
| Seed | 9,263,621 | $0.000100 | 8% | $0.27 | $0.27 | 1x | $0.27 | 8.12% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Astrocyte Pharma Comparisons
Industry
Financing
Details
Astrocyte Pharma Competitors (66)
One of Astrocyte Pharma’s 66 competitors is Lucid Psycheceuticals, a Corporate Backed or Acquired company based in Toronto, Canada.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lucid Psycheceuticals | Corporate Backed or Acquired | Toronto, Canada | ||||
| CervoMed | Formerly VC-backed | Boston, MA | ||||
| Ischemix | Formerly VC-backed | Grafton, MA | ||||
| Metabolic Solutions Development Company | Venture Capital-Backed | Kalamazoo, MI | ||||
| Cytokinetics | Formerly VC-backed | South San Francisco, CA |
Astrocyte Pharma Patents
Astrocyte Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4611724-A1 | Compositions for intravenous administration | Pending | 03-Nov-2022 | ||
| EP-4611724-A4 | Compositions for intravenous administration | Pending | 03-Nov-2022 | ||
| WO-2024097387-A1 | Compositions for intravenous administration | Inactive | 03-Nov-2022 | ||
| EP-4611765-A2 | Fast-dissolving dosage forms and uses thereof | Pending | 03-Nov-2022 | ||
| EP-4611765-A4 | Fast-dissolving dosage forms and uses thereof | Pending | 03-Nov-2022 | A61K31/7076 |
Astrocyte Pharma Signals
Astrocyte Pharma Investors (27)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel Star Ventures | Angel Group | Minority | ||
| Dynagrow Capital | Venture Capital | Minority | ||
| WaterStar Capital | Venture Capital | Minority | ||
| National Institutes of Health | Government | |||
| Chemical Angel Network | Angel Group |
Astrocyte Pharma FAQs
-
When was Astrocyte Pharma founded?
Astrocyte Pharma was founded in 2014.
-
Where is Astrocyte Pharma headquartered?
Astrocyte Pharma is headquartered in Groton, CT.
-
What is the size of Astrocyte Pharma?
Astrocyte Pharma has 9 total employees.
-
What industry is Astrocyte Pharma in?
Astrocyte Pharma’s primary industry is Drug Discovery.
-
Is Astrocyte Pharma a private or public company?
Astrocyte Pharma is a Private company.
-
What is Astrocyte Pharma’s current revenue?
The current revenue for Astrocyte Pharma is .
-
How much funding has Astrocyte Pharma raised over time?
Astrocyte Pharma has raised $26.1M.
-
Who are Astrocyte Pharma’s investors?
Angel Star Ventures, Dynagrow Capital, WaterStar Capital, National Institutes of Health, and Chemical Angel Network are 5 of 27 investors who have invested in Astrocyte Pharma.
-
Who are Astrocyte Pharma’s competitors?
Lucid Psycheceuticals, CervoMed, Ischemix, Metabolic Solutions Development Company, and Cytokinetics are some of the 66 competitors of Astrocyte Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process